FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087390633> ?p ?o ?g. }

• W2087390633 endingPage "266" @default.
• W2087390633 startingPage "257" @default.
• W2087390633 abstract "Hemoglobin degradation products, in particular iron, have been implicated in secondary neuronal injury following intracerebral hemorrhage (ICH). The iron chelator Deferoxamine Mesylate (DFO) exerts diverse neuroprotective effects, reduces perihematoma edema (PHE) and neuronal damage, and improves functional recovery after experimental ICH. We hypothesize that treatment with DFO could minimize neuronal injury and improve outcome in ICH patients. As a prelude to test this hypothesis, we conducted a Phase I, open-label study to determine the tolerability, safety, and maximum tolerated dose (MTD) of DFO in patients with ICH. Intravenous infusions of DFO in doses up to 62 mg/kg/day (up to a maximum of 6000 mg/day) were well-tolerated and did not seem to increase serious adverse events (SAEs) or mortality. We have initiated a multi-center, double-blind, randomized, placebo-controlled, Phase II clinical trial (High Dose Deferoxamine [HI-DEF] in Intracerebral Hemorrhage) to determine if it is futile to move DFO forward to Phase III efficacy evaluation.We will randomize 324 subjects with spontaneous ICH to either DFO at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day) or saline placebo, given by intravenous infusion for 5 consecutive days. Treatment will be initiated within 24 hours after ICH symptom onset. All subjects will be followed for 3 months and will receive standard of care therapy while participating in the study. At 3 months, the proportion of DFO-treated subjects with a good clinical outcome, assessed by modified Rankin Scale, will be compared to the placebo proportion in a futility analysis.The Hi-Def trial is expected to advance our understanding of the pathopgysiology of secondary neuronal injury in ICH and will provide a crucial Go/No Go signal as to whether a Phase III trial to investigate the efficacy of DFO is warranted." @default.
• W2087390633 created "2016-06-24" @default.
• W2087390633 creator A5002815959 @default.
• W2087390633 creator A5033233067 @default.
• W2087390633 creator A5052768521 @default.
• W2087390633 creator A5056211885 @default.
• W2087390633 date "2013-08-13" @default.
• W2087390633 modified "2023-10-13" @default.
• W2087390633 title "High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods" @default.
• W2087390633 cites W1967290285 @default.
• W2087390633 cites W1990282151 @default.
• W2087390633 cites W1995177006 @default.
• W2087390633 cites W1996241764 @default.
• W2087390633 cites W2004872383 @default.
• W2087390633 cites W2005206672 @default.
• W2087390633 cites W2020847830 @default.
• W2087390633 cites W2021648195 @default.
• W2087390633 cites W2030529426 @default.
• W2087390633 cites W2032613630 @default.
• W2087390633 cites W2034456343 @default.
• W2087390633 cites W2049166204 @default.
• W2087390633 cites W2055561763 @default.
• W2087390633 cites W2058323075 @default.
• W2087390633 cites W2067752648 @default.
• W2087390633 cites W2084864775 @default.
• W2087390633 cites W2090421059 @default.
• W2087390633 cites W2092658609 @default.
• W2087390633 cites W2094585602 @default.
• W2087390633 cites W2094992383 @default.
• W2087390633 cites W2107209468 @default.
• W2087390633 cites W2127707745 @default.
• W2087390633 cites W2127886120 @default.
• W2087390633 cites W2138348724 @default.
• W2087390633 cites W2142640478 @default.
• W2087390633 cites W2155311613 @default.
• W2087390633 cites W2157251111 @default.
• W2087390633 cites W2168379311 @default.
• W2087390633 cites W2479717569 @default.
• W2087390633 cites W3028459116 @default.
• W2087390633 cites W4238103798 @default.
• W2087390633 cites W4301655662 @default.
• W2087390633 doi "https://doi.org/10.1007/s12028-013-9861-y" @default.
• W2087390633 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3932442" @default.
• W2087390633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23943316" @default.
• W2087390633 hasPublicationYear "2013" @default.
• W2087390633 type Work @default.
• W2087390633 sameAs 2087390633 @default.
• W2087390633 citedByCount "104" @default.
• W2087390633 countsByYear W20873906332014 @default.
• W2087390633 countsByYear W20873906332015 @default.
• W2087390633 countsByYear W20873906332016 @default.
• W2087390633 countsByYear W20873906332017 @default.
• W2087390633 countsByYear W20873906332018 @default.
• W2087390633 countsByYear W20873906332019 @default.
• W2087390633 countsByYear W20873906332020 @default.
• W2087390633 countsByYear W20873906332021 @default.
• W2087390633 countsByYear W20873906332022 @default.
• W2087390633 countsByYear W20873906332023 @default.
• W2087390633 crossrefType "journal-article" @default.
• W2087390633 hasAuthorship W2087390633A5002815959 @default.
• W2087390633 hasAuthorship W2087390633A5033233067 @default.
• W2087390633 hasAuthorship W2087390633A5052768521 @default.
• W2087390633 hasAuthorship W2087390633A5056211885 @default.
• W2087390633 hasBestOaLocation W20873906332 @default.
• W2087390633 hasConcept C126322002 @default.
• W2087390633 hasConcept C141071460 @default.
• W2087390633 hasConcept C142724271 @default.
• W2087390633 hasConcept C168563851 @default.
• W2087390633 hasConcept C17624336 @default.
• W2087390633 hasConcept C197934379 @default.
• W2087390633 hasConcept C204787440 @default.
• W2087390633 hasConcept C27081682 @default.
• W2087390633 hasConcept C2776672577 @default.
• W2087390633 hasConcept C2777094939 @default.
• W2087390633 hasConcept C2777288759 @default.
• W2087390633 hasConcept C2778375690 @default.
• W2087390633 hasConcept C2780931571 @default.
• W2087390633 hasConcept C3020199598 @default.
• W2087390633 hasConcept C42219234 @default.
• W2087390633 hasConcept C535046627 @default.
• W2087390633 hasConcept C541997718 @default.
• W2087390633 hasConcept C71924100 @default.
• W2087390633 hasConcept C98274493 @default.
• W2087390633 hasConceptScore W2087390633C126322002 @default.
• W2087390633 hasConceptScore W2087390633C141071460 @default.
• W2087390633 hasConceptScore W2087390633C142724271 @default.
• W2087390633 hasConceptScore W2087390633C168563851 @default.
• W2087390633 hasConceptScore W2087390633C17624336 @default.
• W2087390633 hasConceptScore W2087390633C197934379 @default.
• W2087390633 hasConceptScore W2087390633C204787440 @default.
• W2087390633 hasConceptScore W2087390633C27081682 @default.
• W2087390633 hasConceptScore W2087390633C2776672577 @default.
• W2087390633 hasConceptScore W2087390633C2777094939 @default.
• W2087390633 hasConceptScore W2087390633C2777288759 @default.
• W2087390633 hasConceptScore W2087390633C2778375690 @default.
• W2087390633 hasConceptScore W2087390633C2780931571 @default.
• W2087390633 hasConceptScore W2087390633C3020199598 @default.
• W2087390633 hasConceptScore W2087390633C42219234 @default.

• next